Table 5 Patient demographics and oncological characteristics of patients tested positive for COVID-19
2020 (n = 5) | ||
|---|---|---|
n | % | |
Patient demographics | ||
Sex | ||
Male | 5 | 100.00 |
Age | ||
Mean (SD)—years | 60.4 (12.9) | |
Socioeconomic status (IMD) | ||
Low | 4 | 80.00 |
Missing | 1 | 20.00 |
Ethnicity | ||
White British | 2 | 40.00 |
Black African | 1 | 20.00 |
Other | 1 | 20.00 |
Unknown | 1 | 20.00 |
Associated comorbidities | ||
Comorbidities | ||
Hypertension | 3 | 60.00 |
Diabetes | 3 | 60.00 |
Lung conditions | 0 | 0.00 |
Renal impairment | 1 | 20.00 |
Liver conditions | 0 | 0.00 |
Cerebrovascular disease | 0 | 0.00 |
Frailty | 1 | 20.00 |
Long-term steroid use | 0 | 0.00 |
Number of comorbidities | ||
0 | 2 | 40.00 |
1 | 0 | 0.00 |
2 | 1 | 20.00 |
3 or more | 2 | 40.00 |
Medications | ||
Polypharmacy | 3 | 60.00 |
NSAIDs | 0 | 0.00 |
ACE/ARB | 0 | 0.00 |
Beta-blockers | 0 | 0.00 |
Oncological characteristics | ||
Cancer type | ||
Prostate | 2 | 40.00 |
Renal | 2 | 40.00 |
Bladder | 1 | 20.00 |
Testicular | 0 | 0.00 |
SACT | ||
Chemotherapy | 0 | 0.00 |
Immunotherapy | 1 | 20.00 |
Biological/targeted | 2 | 40.00 |
Hormone | 2 | 40.00 |
Treatment paradigm | ||
Palliative | 5 | 100.00 |
COVID-19 severity | ||
COVID-19 severity (WHO criteria) | ||
Asymptomatic | 1 | 20.00 |
Mild | 1 | 20.00 |
Moderate pneumonia | 2 | 40.00 |
Severe pneumonia | 0 | 0.00 |
COVID-related death | 1 | 20.00 |